Medline Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Revenue	28,432	25,507	23,231	21,448
Revenue Growth (YoY)	11.47%	9.80%	8.31%	-
Cost of Revenue	20,914	18,531	17,346	16,231
Gross Profit	7,518	6,976	5,885	5,217
Selling, General & Admin	4,567	4,108	3,867	3,676
Amortization of Goodwill & Intangibles	704	685	662	660
Other Operating Expenses	68	35	-55	20
Operating Expenses	5,339	4,828	4,474	4,356
Operating Income	2,179	2,148	1,411	861
Interest Expense	-945	-1,144	-1,213	-899
Interest & Investment Income	133	280	237	27
Currency Exchange Gain (Loss)	-88	7	-11	11
Other Non Operating Income (Expenses)	-6	-11	1	10
EBT Excluding Unusual Items	1,273	1,280	425	10
Legal Settlements	33	-2	-161	-
Other Unusual Items	-58	-32	-	-
Pretax Income	1,248	1,246	264	10
Income Tax Expense	91	46	30	35
Earnings From Continuing Operations	1,157	1,200	234	-25
Minority Interest in Earnings	2	-	-	-
Net Income	1,159	1,200	234	-25
Net Income to Common	1,159	1,200	234	-25
Net Income Growth	-3.42%	412.82%	-	-
Shares Outstanding (Basic)	810	17,467	17,500	-
Shares Outstanding (Diluted)	810	17,467	17,500	-
Shares Change (YoY)	-95.36%	-0.19%	-	-
EPS (Basic)	1.43	0.07	0.01	-
EPS (Diluted)	1.43	0.07	0.01	-
EPS Growth	1982.77%	413.80%	-	-
Free Cash Flow	1,264	1,405	1,400	-67
Free Cash Flow Per Share	1.56	0.08	0.08	-
Gross Margin	26.44%	27.35%	25.33%	24.32%
Operating Margin	7.66%	8.42%	6.07%	4.01%
Profit Margin	4.08%	4.71%	1.01%	-0.12%
Free Cash Flow Margin	4.45%	5.51%	6.03%	-0.31%
EBITDA	3,190	3,125	2,362	1,794
EBITDA Margin	11.22%	12.25%	10.17%	8.36%
D&A For EBITDA	1,011	977	951	933
EBIT	2,179	2,148	1,411	861
EBIT Margin	7.66%	8.42%	6.07%	4.01%
Effective Tax Rate	7.29%	3.69%	11.36%	350.00%

Updated Feb 25, 2026. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q